🔗 Share this article WHO Sounds Warning Over Critical Lack of Obesity Jabs Fewer than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the therapies. With over a billion individuals worldwide currently living with obesity, it is urging broader and more equitable access to this class of drugs. Based on projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken. "Our latest guidelines acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the jabs that can help people shift substantial body mass, says the body. Weight-Loss Drug Scarcity Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, per the health organization. The advice calls on nations and manufacturers to increase availability, by strategies such as licensing agreements. A patent on a key compound – the main ingredient of the drug Wegovy – is due to expire in multiple nations in 2026. How Weight-Loss Drugs Function The injections mimick a biological compound to slow digestion, curb appetite and enhance the sense of being full so people reduce food intake. Patients typically see weight reduction after several weeks of beginning the once-weekly jabs. Evidence indicates patients may see weight return within a year of discontinuing the treatment, because their usual food cravings resume. To be above a healthy weight raises your chance for developing medical conditions, like diabetes, heart disease, stroke, and certain malignancies. Excess weight concerns people in every country and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
Fewer than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the therapies. With over a billion individuals worldwide currently living with obesity, it is urging broader and more equitable access to this class of drugs. Based on projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken. "Our latest guidelines acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the jabs that can help people shift substantial body mass, says the body. Weight-Loss Drug Scarcity Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, per the health organization. The advice calls on nations and manufacturers to increase availability, by strategies such as licensing agreements. A patent on a key compound – the main ingredient of the drug Wegovy – is due to expire in multiple nations in 2026. How Weight-Loss Drugs Function The injections mimick a biological compound to slow digestion, curb appetite and enhance the sense of being full so people reduce food intake. Patients typically see weight reduction after several weeks of beginning the once-weekly jabs. Evidence indicates patients may see weight return within a year of discontinuing the treatment, because their usual food cravings resume. To be above a healthy weight raises your chance for developing medical conditions, like diabetes, heart disease, stroke, and certain malignancies. Excess weight concerns people in every country and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.